Voloridge Investment Management LLC Has $14.25 Million Stock Position in InMode Ltd. (NASDAQ:INMD)

Voloridge Investment Management LLC reduced its position in InMode Ltd. (NASDAQ:INMD - Free Report) by 19.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 853,541 shares of the healthcare company's stock after selling 203,193 shares during the quarter. Voloridge Investment Management LLC owned about 1.23% of InMode worth $14,254,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Barclays PLC increased its holdings in InMode by 113.5% in the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock valued at $2,876,000 after purchasing an additional 90,173 shares in the last quarter. DGS Capital Management LLC lifted its holdings in InMode by 129.7% in the fourth quarter. DGS Capital Management LLC now owns 24,704 shares of the healthcare company's stock worth $413,000 after acquiring an additional 13,948 shares during the last quarter. Meritage Portfolio Management lifted its holdings in InMode by 12.3% in the fourth quarter. Meritage Portfolio Management now owns 16,575 shares of the healthcare company's stock worth $277,000 after acquiring an additional 1,810 shares during the last quarter. Harvey Capital Management Inc. lifted its holdings in InMode by 1.4% in the fourth quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company's stock worth $860,000 after acquiring an additional 700 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of InMode by 14.6% during the fourth quarter. Principal Financial Group Inc. now owns 99,562 shares of the healthcare company's stock worth $1,663,000 after buying an additional 12,661 shares during the period. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Stock Performance

Shares of NASDAQ INMD traded up $0.14 during mid-day trading on Thursday, hitting $14.53. 203,949 shares of the stock were exchanged, compared to its average volume of 1,181,309. The company has a market cap of $918.11 million, a P/E ratio of 6.18 and a beta of 2.02. The stock's fifty day simple moving average is $15.36 and its two-hundred day simple moving average is $17.13. InMode Ltd. has a twelve month low of $13.68 and a twelve month high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last released its earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a return on equity of 18.25% and a net margin of 45.91%. The business had revenue of $77.87 million for the quarter, compared to analyst estimates of $82.21 million. During the same period in the prior year, the firm posted $0.32 EPS. InMode's revenue was down 3.0% on a year-over-year basis. As a group, equities research analysts predict that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on INMD shares. Robert W. Baird downgraded InMode from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $22.00 to $16.00 in a research report on Monday, April 28th. BTIG Research downgraded InMode from a "buy" rating to a "neutral" rating in a research report on Tuesday, April 29th. Canaccord Genuity Group cut their target price on InMode from $17.00 to $15.00 and set a "hold" rating for the company in a research report on Tuesday, April 29th. Barclays cut their target price on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Finally, Jefferies Financial Group cut their target price on InMode from $16.00 to $15.00 and set a "hold" rating for the company in a research report on Monday, April 14th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, InMode currently has an average rating of "Hold" and an average target price of $18.54.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.